A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501686-47-00

Enrollment

Registered

2022-11-04

Start date

2022-02-28

Completion date

2025-08-25

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed/refractory chronic lymphocytic leukemia relapsed/refractory small lymphocytic leukemia

Brief summary

Phase I: Incidence of (serious) adverse events, including dose-limiting toxicities (DLT), Phase II: Best objective response rate per iwCLL response criteria (Lugano classification for Richter's transformation)

Interventions

DRUGBCN-CP01

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase I: Incidence of (serious) adverse events, including dose-limiting toxicities (DLT), Phase II: Best objective response rate per iwCLL response criteria (Lugano classification for Richter's transformation)	—

Countries

Belgium, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 8, 2026